ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / PRGO / dividends
AUPH (74) XNCR (47) IMNM (26) VERA (31) ⌘ Pro Terminal β†’

Perrigo Company plc (PRGO) Dividend Safety Gauge & 10-Year DRIP Compounder

$15.75 -0.19% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.71

Perrigo Company plc (PRGO) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D β€’ SELL / AVOID Cap $2.19B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRGO Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is PRGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Perrigo Company plc (NYSE: PRGO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $15.75 (-0.19% 1D, market cap $2.19B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, PRGO ranks #273 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does PRGO compare to AUPH and XNCR in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRGO carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of 35.1%, and ROIC of -13.6%. By comparison, AUPH (Aurinia Pharmaceuticals Inc) holds a B grade (74/100 RQD, P/E 8.0x, ROIC 16.5%, cap $2.22B) and XNCR (Xencor Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -21.3%, cap $2.22B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while AUPH leads on capital efficiency (16.5% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRGO?
β–Ό

Per PRGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001585364), Perrigo Company plc generated $4.25B in revenue (-2.8% YoY), -$1.43B in net income, and $145.1M in free cash flow against $8.54B in total assets and $3.60B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $15.72 (-0.22%)🧬 Disciplined Float (-0.40% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 3.4% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (49/100 Β· D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D
025507510049
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D+ Β· Rk D-
Cash (8)Whales (15)SEC (5)Macro (12)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-4.1% Base Target
$22 Bull$15 Base$12 Bear
πŸ“¬ FREE PRGO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for PRGO)Realized 20D OHLCV Swing Band: Β±8.1%
Deterministic 5-Pillar Attribution (49/100 Composite)
πŸ” WHY PRGO SCORES 49/100 (D) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+15/20 pts (31% of score)

20D Institutional Volume Accumulation (Β±8.1% realized swing band)

β–² #2 Bullish Driver: Macro Regime Fit+12/20 pts (24% of score)

FRED Regime Γ— Technicals: 57% of 52W Range β€’ RSI-14 at 54.8 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: SEC 10-K Forensic Risk5/20 pts (-15 pt drag)

Balance-sheet & 10-K footnote risk deducts 15 pts from forensic ceiling

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
41
Grade D$15.37+5.2% Next Q
Q2 (-2Q)
44
Grade D$16.17-0.9% Next Q
Q3 (-1Q)
46
Grade D$16.02-1.7% Next Q
Current
49
Grade D$15.75-5.4% Hist 90D Ξ±
Trajectory: D (41) β†’ D (49)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a PRGO Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While PRGO currently carries a cautious 49/100 (D) rating due to SEC 10-K Forensic Risk (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.89) and Max Pain ($16.54) forces dealer call-delta covering toward $21.68.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRGOβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œPRGO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 49%NO 51%Trade / Inspect Odds β†’
CASH DIVIDEND + BUYBACK YIELD
9.02% Total Yield
7.22% Cash ($1.14/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
68/100 β€’ SAFE COVERAGE
FREE CASH FLOW PAYOUT RATIO
71.3% of FCF
8 consecutive years of payout growth
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (12.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $32,473

Est. Year-10 Shareholder Yield: $2,929/yr
$11.3K
Yr 1
$12.7K
Yr 2
$14.2K
Yr 3
$16.0K
Yr 4
$18.0K
Yr 5
$20.3K
Yr 6
$22.8K
Yr 7
$25.7K
Yr 8
$28.9K
Yr 9
$32.5K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRGO)

  • βœ“Walkthrough of PRGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
PRGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +38.28%πŸ“ HORIZONTAL RANGE
2026-11-03O $15.90H $15.90L $15.75C $15.75VOL 3.35M
RES: $17.45SUP: $8.70SMA50: $14.89SMA200: $12.45
$17.31$15.16$13.02$10.88$8.73RES $17.45SUP $8.70$15.752026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ PRGO Butterfly Map β†’ + Track PRGO β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -2.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PRGO today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for PRGO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PRGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRGO)

Health Care Rank #273 of 1015 βš”οΈ AUPH vs PRGO Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (PRGO vs. AUPH, XNCR, IMNM, VERA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Perrigo Company plc (PRGO) ranks #273 by composite RQD confidence (49/100, grade D) and #241 by equity capitalization ($2.19B). Within this direct 5-issuer industry benchmark cohort, AUPH leads on earnings valuation at 8.0x trailing P/E, while AUPH leads on capital efficiency and profitability with 16.5% ROIC and 88.5% gross margin. AUPH currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with PRGO at 49/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PRGO ACTIVE
Perrigo Company plc
D 49/100 β€” 35.1% -13.6% -0.19% $2.19B Benchmark Subject
AUPH
Aurinia Pharmaceuticals Inc
B 74/100 8.0x 88.5% 16.5% -3.06% $2.22B /auph-vs-prgo β†’
XNCR
Xencor Inc.
D 47/100 β€” β€” -21.3% -0.54% $2.22B /xncr-vs-prgo β†’
IMNM
Immunome Inc.
E 26/100 β€” β€” -35.0% +7.58% $2.15B /imnm-vs-prgo β†’
VERA
Vera Therapeutics Inc. (Class A)
E 31/100 β€” β€” -35.0% -2.36% $2.23B /vera-vs-prgo β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001585364 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Perrigo Company plc (PRGO) reported GAAP revenue of $4.25B (-2.8% vs. FY2024 revenue of $4.37B , and -8.6% cumulative change since FY2023) , GAAP net income of -$1.43B, operating cash flow of $238.5M, and free cash flow of $145.1M (-40.7% YoY). On the balance sheet, PRGO closed FY2025 with $8.54B in total assets against $3.60B in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $4.25B -$1.43B $238.5M $145.1M $8.54B $3.60B
FY2024 (FY) 2024-12-31 $4.37B -$171.8M $362.9M $244.6M $9.65B $3.58B
FY2023 (FY) 2023-12-31 $4.66B -$12.7M $405.5M $405.5M β€” β€”

3. PRGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Perrigo Company plc (NYSE: PRGO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $15.75 (-0.19% 1D, market cap $2.19B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, PRGO ranks #273 in composite RQD confidence.

How does PRGO compare to AUPH and XNCR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRGO carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of 35.1%, and ROIC of -13.6%. By comparison, AUPH (Aurinia Pharmaceuticals Inc) holds a B grade (74/100 RQD, P/E 8.0x, ROIC 16.5%, cap $2.22B) and XNCR (Xencor Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -21.3%, cap $2.22B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while AUPH leads on capital efficiency (16.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRGO?

Per PRGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001585364), Perrigo Company plc generated $4.25B in revenue (-2.8% YoY), -$1.43B in net income, and $145.1M in free cash flow against $8.54B in total assets and $3.60B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRGO trading relative to its 50-day, 200-day, and 52-week technical levels?

PRGO last traded at $15.75 (-0.19% on volume of 2,007,502 shares), positioning the stock +5.78% above its 50-day simple moving average ($14.89) and +26.51% above its 200-day simple moving average ($12.45). Across its 52-week range of $9.23 to $20.65, PRGO sits at the 57.1% percentile with a 14-day RSI of 54.8 (NEUTRAL RANGE) and an implied next-earnings move of Β±8.1% ($14.47 to $17.03).

Direct Sub-Reports: PRGO RQD Cockpit PRGO 12M Forecast PRGO Earnings & Move PRGO Dividends & DRIP PRGO Insiders & 13F PRGO Whale Options PRGO Profit Sankey PRGO News & Why
ROARABLE RATING BRIEF β€’ RQD 49/100 (D) βœ“ SEC XBRL & RQD VERIFIED

PRGO β€” Perrigo Company plc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Perrigo Company plc (PRGO) earns a live Roarable RQD composite score of 49/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $15.75 (-0.19% 1D, market capitalization $2.19B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -13.6%, gross margin of 35.1%, operating margin of -26.4%, and free cash flow yield of 6.58%.
  • Whale 13F & Options Flow (15/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 5/9, and Debt/Equity of 1.23x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Perrigo Company plc is a NYSE-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. The company carries a market capitalization of $2.2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Perrigo Company plc (PRGO) reported $4.25B in annual revenue (up from $4.37B in FY2024, -2.8% YoY) and -$1.43B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($4.66B revenue, -$12.7M net income) through FY2025, PRGO scaled operating cash flow to $238.5M and free cash flow to $145.1M, backed by $8.54B in total assets against $3.60B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D β€’ RQD 49/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of 6.58% and institutional whale pillar of 15/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $9.23 – $20.65 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -26.4% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), PRGO carries a macro regime beta of 1.00 and gross margin of 35.1%.

  • Key Question #1: Can PRGO sustain or expand its -26.4% operating margin and -13.6% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $4.25B and free cash flow of $145.1M, how will capital allocation balance growth reinvestment against $3.60B in total debt?
  • Key Question #3: How sensitive is PRGO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PRGO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Perrigo Company plc (PRGO) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to PRGO Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PRGO Bull vs. Bear Conversation Board β€” What's Your Call at $15.75?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRGO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PRGO:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER β€’ Cross-Asset Macro Desk πŸ‚ BULLISH 🎯 Target: $18.78 (+19.0%)
πŸ“Œ Pinned Debate

A 6.58% FCF yield and 7.22% dividend yield offer cash-return support at a $15.90 price despite the weak balance sheet.

Don't sleep on PRGO's setup in Health Care. A 6.58% FCF yield and 7.22% dividend yield offer cash-return support at a $15.90 price despite the weak balance sheet.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (49/100) backs up the fundamental quality.

CapAlloc_Nerd πŸ‚ BULL

@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (35.1%) holds, EPS grows into the multiple faster than bears think.

SK SkepticalCFA RQD DEBATE OPENER β€’ Fundamental Contrarian 🐻 BEARISH 🎯 Target: $12.15 (-23.0%)
Spot @ $15.78

Negative ROIC of -13.6%, an Altman Z of 0.2, and FY 2025 net loss of -$1.43B point to balance-sheet distress against $3.60B of debt

Fading this rally in PRGO at $15.78. Negative ROIC of -13.6%, an Altman Z of 0.2, and FY 2025 net loss of -$1.43B point to balance-sheet distress against $3.60B of debt.. With a beta of 1.0 and the stock sitting at $15.78 (52-wk range $9.23–$20.65), the easy multiple expansion is already priced in.

LIVE TAPE